



# Multimorbidity, functional limitations, and outcomes: Interactions in a population-based cohort of older adults

Alanna M Chamberlain<sup>1,2</sup> , Lila J Finney Rutten<sup>1,2</sup>, Debra J Jacobson<sup>1,2</sup>, Chun Fan<sup>1</sup>, Patrick M Wilson<sup>1,2</sup>, Walter A Rocca<sup>1,3</sup>, Véronique L Roger<sup>1,4</sup> and Jennifer L St Sauver<sup>1,2</sup>

## Abstract

**Objective:** To understand the interaction of multimorbidity and functional limitations in determining health-care utilization and survival in older adults.

**Methods:** Olmsted County, Minnesota, residents aged 60–89 years in 2005 were categorized into four cohorts based on the presence or absence of multimorbidity ( $\geq 3$  chronic conditions from a list of 18) and functional limitations ( $\geq 1$  limitation in an activity of daily living from a list of 9), and were followed through December 31, 2016. Andersen–Gill and Cox regression estimated hazard ratios (HRs) for emergency department (ED) visits, hospitalizations, and death using persons with neither multimorbidity nor functional limitations as the reference (interaction analyses).

**Results:** Among 13,145 persons, 34% had neither multimorbidity nor functional limitations, 44% had multimorbidity only, 4% had functional limitations only, and 18% had both. Over a median follow-up of 11 years, 5906 ED visits, 2654 hospitalizations, and 4559 deaths occurred. Synergistic interactions on an additive scale of multimorbidity and functional limitations were observed for all outcomes; however, the magnitude of the interactions decreased with advancing age. The HR (95% confidence interval) for death among persons with both multimorbidity and functional limitations was 5.34 (4.40–6.47) at age 60–69, 4.16 (3.59–4.83) at age 70–79, and 2.86 (2.45–3.35) at age 80–89 years.

**Conclusion:** The risk of ED visits, hospitalizations, and death among persons with both multimorbidity and functional limitations is greater than additive. The magnitude of the interaction was strongest for the youngest age group, highlighting the importance of interventions to prevent and effectively manage multimorbidity and functional limitations early in life.

## Keywords

High-need patients, multimorbidity, functional limitations, activities of daily living, death, hospitalization, health-care utilization, health outcomes, interactions

Received 12 February 2019; accepted: 8 August 2019

## Introduction

The number of persons aged 65 years and older in the United States is projected to increase twofold by the year 2050, representing 20% of the total population.<sup>1</sup> As a result of the aging population, along with advancements in life-prolonging medical care, an increased number of persons with multimorbidity and complex medical needs are expected, together with increased health-care utilization and expenditures.<sup>1–3</sup> In the United States, 1% of adults

<sup>1</sup> Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

<sup>2</sup> Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA

<sup>3</sup> Department of Neurology, Mayo Clinic, Rochester, MN, USA

<sup>4</sup> Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

### Corresponding author:

Alanna M Chamberlain, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Email: chamberlain.alanna@mayo.edu



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons

Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

account for more than 20% of health-care expenditures, and the top 5% of spenders account for 50% of all health-care expenditures.<sup>4,5</sup> The vast majority of high-cost patients have three or more chronic conditions, and nearly half of patients in the top 5% of annual medical expenditures have at least three chronic conditions as well as functional limitations.<sup>6</sup> Thus, an inevitable result of the aging population and advances in medical care is an increasing number of complex, high-cost patients who will contribute to escalating medical costs.

The population of complex, high-need patients is diverse, and there are different definitions of complex needs in the literature.<sup>7,8</sup> The Commonwealth Fund defines persons with high needs as those who have both multimorbidity (having three or more chronic diseases) and functional limitations (limitation in at least one basic or instrumental activity of daily living (ADL) affecting their ability to care for themselves or to perform routine daily tasks).<sup>6</sup> In the Medical Expenditure Panel Survey, the persons who meet the definition of high need<sup>6</sup> experienced higher rates of emergency department (ED) visits and hospitalizations, higher health-care spending, and higher out-of-pocket costs than those with multimorbidity but without functional limitations.<sup>6</sup> Therefore, we hypothesized that multimorbidity and functional limitations may have different underlying mechanisms, and that having both imparts a larger risk of adverse health outcomes than expected (synergistic interaction).

With increasing numbers of older, high-need patients, it is imperative to better understand the outcomes of high-need patients. However, only few data sets in the United States and worldwide contain information on patient-reported outcomes assessing functional limitations. As such, studies utilizing administrative claims data or electronic health records data are unable to provide this information. Therefore, the aim of our study was to describe the interaction of multimorbidity with functional limitations on health outcomes, including ED visits, hospitalizations, and death, in a large population of older adults.

## Methods

### Study population

This study was conducted using the Rochester Epidemiology Project (REP) medical records-linkage system.<sup>9–12</sup> The REP captures all health-care information from the few providers who deliver most of the health care to the residents of Olmsted County, Minnesota, allowing virtually complete capture of residents' health-care utilization and outcomes. Importantly, demographic characteristics of Olmsted County, Minnesota, are representative of the state of Minnesota and the Upper Midwest region of the United States, and age- and sex-specific mortality rates in Olmsted County are similar to national data, supporting the generalizability of findings from this population.<sup>10</sup> For the current

study, we examined the 2005 residents of Olmsted County, Minnesota, aged 60–89 years who were alive as of January 1, 2006 ( $n = 16,267$ ). We further restricted our sample to persons with available data on ADLs between 2004 and 2005 ( $n = 13,145$ ; 81% of the total population). This study was approved by the Mayo Clinic and Olmsted Medical Center Institutional Review Boards.

### Assessment of multimorbidity and ADLs

We retrieved diagnostic codes for 20 chronic conditions defined by the US Department of Health and Human Services as important for studies of multimorbidity.<sup>13,14</sup> However, less than 1% of the population had autism, hepatitis, or human immunodeficiency virus, so these conditions were excluded. Anxiety was added to the list, resulting in a total of 18 chronic conditions. The diagnostic codes used to define the 18 chronic conditions are provided in Supplementary Table 1. To reduce the possibility for false-positive or rule-out diagnoses, we required two occurrences of a code (either the same diagnostic code or two different diagnostic codes within the same code set) separated by more than 30 days and occurring between 2000 and 2005. Multimorbidity was defined as having 3 or more of the 18 chronic conditions.

We ascertained difficulty with at least one ADL using a questionnaire that was administered on at least a yearly basis to persons seen at one of the institutions that participates in the REP (Mayo Clinic). A total of nine ADLs, including both basic and instrumental ADLs, were ascertained by asking the person to select all of the activities which they had difficulty performing on their own from a list (see Table 1). For example, a person could have selected needing help with housekeeping or with climbing stairs. Only persons with at least one questionnaire between 2004 and 2005 were included, and when persons had multiple questionnaires available, we used the most complete questionnaire that was closest to January 1, 2006. Functional limitations was defined as reporting difficulty with one or more of the nine ADLs.

Using the framework from the Commonwealth Fund to identify high-need patients,<sup>6</sup> persons were categorized into four discrete cohorts based on the presence or absence of multimorbidity and functional limitations: (1) neither multimorbidity nor functional limitations, (2) multimorbidity but no functional limitations, (3) no multimorbidity but functional limitations, and (4) both multimorbidity and functional limitations.

### Outcomes ascertainment

Hospitalizations and ED visits for any cause, and deaths from any cause were obtained from January 1, 2006 through December 31, 2016 from the REP. In-hospital transfers or transfers between hospitals were combined into a single encounter and were counted as a single

**Table 1.** Demographic characteristics and chronic conditions in four cohorts defined by functional limitation and multimorbidity status.<sup>a</sup>

	Neither functional limitations nor multimorbidity (N = 4487)	No functional limitations but multimorbidity (N = 5797)	Functional limitations but no multimorbidity (N = 538)	Both functional limitations and multimorbidity (N = 2323)
<b>Demographics</b>				
Age (years)	66.6 (62.7, 72.3)	71.5 (65.7, 77.7)	72.9 (65.0, 80.7)	77.4 (70.3, 82.8)
<b>Age group</b>				
60–69	2891 (64.4%)	2431 (41.9%)	218 (40.5%)	541 (23.3%)
70–79	1249 (27.8%)	2311 (39.9%)	168 (31.2%)	846 (36.4%)
80–89	347 (7.7%)	1055 (18.2%)	152 (28.3%)	936 (40.3%)
Female sex	2491 (55.5%)	2994 (51.7%)	358 (66.5%)	1522 (65.5%)
<b>Race</b>				
White	4243 (95.2%)	5590 (96.7%)	481 (90.2%)	2212 (95.4%)
Black	46 (1.0%)	39 (0.7%)	29 (5.4%)	43 (1.9%)
Asian	114 (2.6%)	88 (1.5%)	19 (3.6%)	36 (1.6%)
Other	54 (1.2%)	64 (1.1%)	4 (0.8%)	27 (1.2%)
<b>Ethnicity</b>				
Hispanic	91 (2.0%)	96 (1.7%)	9 (1.7%)	32 (1.4%)
Non-Hispanic	4396 (98.0%)	5701 (98.3%)	529 (98.3%)	2291 (98.6%)
<b>Education</b>				
<High school	210 (4.7%)	435 (7.5%)	95 (17.8%)	368 (15.9%)
High school/some college	2453 (54.7%)	3349 (57.8%)	287 (53.8%)	1399 (60.4%)
College or advanced degree	1819 (40.6%)	2007 (34.7%)	152 (28.5%)	549 (23.7%)
<b>Marital status</b>				
Married/living together	3034 (67.7%)	3521 (60.8%)	222 (41.3%)	1004 (43.2%)
Non-married	1451 (32.4%)	2273 (39.2%)	316 (58.7%)	1318 (56.8%)
<b>Chronic conditions</b>				
Hypertension	1369 (30.5%)	4547 (78.4%)	192 (35.7%)	1978 (85.2%)
Congestive heart failure	6 (0.1%)	362 (6.2%)	13 (2.4%)	444 (19.1%)
Coronary artery disease	189 (4.2%)	2121 (36.6%)	23 (4.3%)	1018 (43.8%)
Cardiac arrhythmia	236 (5.3%)	1768 (30.5%)	34 (6.3%)	945 (40.7%)
Hyperlipidemia	1586 (35.4%)	4616 (79.6%)	105 (19.5%)	1560 (67.2%)
Stroke	33 (0.7%)	528 (9.1%)	6 (1.1%)	402 (17.3%)
Arthritis	702 (15.7%)	2290 (39.5%)	132 (24.5%)	1233 (53.1%)
Asthma	90 (2.0%)	479 (8.3%)	12 (2.2%)	228 (9.8%)
Cancer	713 (15.9%)	2273 (39.2%)	62 (11.5%)	858 (36.9%)
Chronic kidney disease	16 (0.4%)	475 (8.2%)	3 (0.6%)	412 (17.7%)
Chronic obstructive pulmonary disease	88 (2.0%)	653 (11.3%)	35 (6.5%)	549 (23.6%)
Dementia	21 (0.5%)	142 (2.5%)	34 (6.3%)	313 (13.5%)
Depression	150 (3.3%)	890 (15.4%)	24 (4.5%)	634 (27.3%)
Diabetes	209 (4.7%)	1779 (30.7%)	32 (6.0%)	828 (35.6%)
Osteoporosis	277 (6.2%)	825 (14.2%)	35 (6.5%)	460 (19.8%)
Schizophrenia	10 (0.2%)	44 (0.8%)	5 (0.9%)	102 (4.4%)
Substance abuse disorders (drug and alcohol)	14 (0.3%)	99 (1.7%)	2 (0.4%)	75 (3.2%)
Anxiety	118 (2.6%)	762 (13.1%)	12 (2.2%)	408 (17.6%)
Number of chronic conditions	1 (1, 2)	4 (3, 5)	2 (1, 2)	5 (4, 7)
<b>ADLs—need help with:</b>				
Feeding yourself	0	0	41 (7.6%)	111 (4.8%)
Dressing yourself	0	0	95 (17.7%)	361 (15.5%)
Using the toilet	0	0	52 (9.7%)	209 (9.0%)
Housekeeping	0	0	194 (36.1%)	941 (40.5%)
Climbing stairs	0	0	335 (62.3%)	1614 (69.5%)
Bathing	0	0	99 (18.4%)	510 (22.0%)
Walking	0	0	252 (46.8%)	1076 (46.3%)
Using transportation	0	0	128 (23.8%)	549 (23.6%)
Managing medications	0	0	86 (16.0%)	539 (23.2%)
Number of ADLs	0 (0, 0)	0 (0, 0)	2 (1, 3)	2 (1, 3)

ADLs: activities of daily living.

<sup>a</sup>Values are presented as median (25th, 75th percentile) or N (%).

hospitalization. However, ED visits that resulted in a hospitalization were counted as both an ED visit and a hospitalization.

### Statistical analysis

For each of the four cohorts, demographic characteristics were reported as median (25th, 75th percentile) or number (percent), and the proportion of persons with each of the 18 comorbidities was also reported. Follow-up began on January 1, 2006 and continued until death, last clinical encounter, or December 31, 2016, whichever came first. Persons were stratified by decade of age on January 1, 2005 (60–69, 70–79, and 80–89 years), and the rates of each outcome per 1000 person-years were calculated, counting multiple events per person for ED visits and hospitalizations. For ED visits and hospitalizations, the mean cumulative functions over follow-up for the four cohorts were plotted using a nonparametric estimator.<sup>15</sup> The basis for this function is that each person can be represented by a stepwise curve of cumulative number of ED visits or hospitalizations over follow-up; thus, this function is appropriate to use when there may be multiple recurrent events per person. The mean cumulative function is the pointwise average of all the individual cumulative measurement curves. In addition, Kaplan–Meier plots were constructed to visualize survival over follow-up for the four cohorts. The mean cumulative function and Kaplan–Meier plots are crude representations of differences between groups, and were not adjusted for differences in patient characteristics between the four cohorts.

Andersen–Gill modeling, which allows for multiple repeated outcome events, was used to estimate hazard ratios (HRs) of ED visits and hospitalizations, while Cox proportional hazards regression was used to estimate HRs for death. Persons with neither multimorbidity nor functional limitations served as the reference group for the Andersen–Gill and Cox models. The HRs were adjusted for age (to account for residual confounding), sex, race (White, Black, Asian, other), ethnicity (Hispanic, non-Hispanic), education (less than high school, high school or some college, college or advanced degree), and marital status (married or living together, non-married). Additive interactions between multimorbidity and functional limitations were tested using the relative risk due to the interaction (RERI) statistic as described by Li and Chambless.<sup>16</sup> The RERI is calculated as  $HR_{12} - HR_1 - HR_2 + 1$ , where  $HR_{12}$  is the HR for those with both multimorbidity and functional limitations versus those with neither,  $HR_1$  is the HR for those with multimorbidity only versus those with neither, and  $HR_2$  is the HR for those with functional limitations only versus those with neither multimorbidity nor functional limitations. This statistic tested whether the observed joint effects of multimorbidity and functional limitations on each outcome were greater than expected assuming independence. Analyses were performed using

SAS statistical software, version 9.4 (SAS Institute Inc., Cary, North Carolina, USA).


### Results

A total of 13,145 Olmsted County residents aged 60–89 in 2005 had available ADL data and were included in the analyses (81% of the population enumerated by the REP). Persons included in the analyses were slightly older (median age 71 vs. 68;  $p < 0.001$ ), more likely to be female (56% vs. 51%;  $p < 0.001$ ), more highly educated (34% vs. 26% with a college or advanced degree;  $p < 0.001$ ), had a higher prevalence of all of the 18 individual chronic conditions, and a higher number of chronic conditions (median number of chronic conditions 3 vs. 2;  $p < 0.001$ ) compared to persons excluded.

The baseline characteristics of the four cohorts are shown in Table 1. The cohorts differed in demographic characteristics and in types of chronic conditions. Of the 13,145 persons in our study, 2323 (18%) had both functional limitations and multimorbidity. These persons were the oldest of the four cohorts, and were most similar to persons with functional limitations but no multimorbidity regarding sex, education level, and marital status. The majority of persons with both multimorbidity and functional limitations had between 3 and 7 chronic conditions (3, 18%; 4, 22%; 5, 18%; 6, 16%; and 7, 12%) and difficulty with 1 (40%), 2 (25%), or 3 (13%) ADLs. More than half of these persons had hypertension (85%), hyperlipidemia (67%), and arthritis (53%), and the most frequently reported ADL limitations were with climbing stairs (69%), walking (46%), and housekeeping (41%) (Table 1).

Over a median follow-up of 11 years, a total of 4559 deaths, 2654 hospitalizations, and 5906 ED visits occurred. The lowest survival and highest cumulative number of hospitalizations and ED visits were observed for persons with both multimorbidity and functional limitations, followed by persons with functional limitations only, multimorbidity only, and neither (who experienced the best survival and the lowest risk of ED visits and hospitalizations) (Figures 1 and 2). The median number of hospitalizations per person was 1 for persons aged 60–69 at baseline, 2 for persons aged 70–79, and 3 for persons aged 80–89 at baseline. The median number of ED visits per person was 2 for persons aged 60–69 and 4 for persons aged 70–79 and 80–89. Within each decade of age, the rates of death, hospitalizations, and ED visits were highest among persons with both functional limitations and multimorbidity (Table 2). As expected, the oldest persons had the highest rates of all outcomes, and persons aged 80–89 with functional limitations and multimorbidity had rates of 5.16 per 1000 person-years for death, 6.60 per 1000 person-years for hospitalizations, and 7.03 per 1000 person-years for ED visits.

After adjustment for age, sex, race, ethnicity, marital status, and education, the highest risks of death, hospitalization, and ED visits were observed in persons with both




**Figure 1.** Kaplan–Meier survival curves in four cohorts defined by functional limitation and multimorbidity status.

multimorbidity and functional limitations (Table 2, Figure 3). Persons with functional limitations only experienced higher risks of death than persons with multimorbidity only. However, for hospitalization and ED visits, similar associations were observed for persons with multimorbidity only and functional limitations only.

Interactions between multimorbidity and functional limitations were tested on the additive scale for each outcome, and a synergistic effect of multimorbidity and functional limitations was observed for all outcomes. For death, the interaction was highly significant for persons aged 60–69 ( $p < 0.01$ ) and borderline significant for persons aged 70–79 ( $p = 0.06$ ) and 80–89 ( $p = 0.04$ ). For hospitalizations and ED visits, the interactions between multimorbidity and functional limitations were highly significant for all age groups ( $p < 0.01$ ). These findings suggest that the impact of both multimorbidity and functional limitations on outcomes is greater than would be expected assuming additivity of effects. Furthermore, for each outcome, a similar pattern of association was observed for each age group; however, the magnitude of the interactions was strongest in the youngest age group and attenuated with increasing age. For example, the HR (95% confidence interval) for death among persons with both functional limitations and multimorbidity was 5.34 (4.40–6.47) for persons aged 60–69, 4.16 (3.59–4.83) for persons aged 70–79, and 2.86 (2.45–3.35) for persons aged 80–89.

## Discussion

In this large population of older adults, we observed an increased risk of ED visits, hospitalizations, and death among high-need patients (defined as persons with both multimorbidity and functional limitations). Few persons had functional limitations without multimorbidity, but



**Figure 2.** Mean cumulative hazard function curve for hospitalizations (top panel) and ED visits (bottom panel) in four cohorts defined by functional limitation and multimorbidity status. ED: emergency department.

these persons tended to have higher rates of death than persons with multimorbidity alone. For all outcomes, synergistic effects of multimorbidity and functional limitations were observed on an additive scale, whereby persons with both multimorbidity and functional limitations experienced greater-than-expected risks assuming additivity of effects. The patterns of association were similar for all age groups; however, the magnitude of the interaction was strongest for the youngest age group and attenuated with increasing age.

Persons with both multimorbidity and functional limitations experienced the poorest health-care outcomes, and multimorbidity and functional limitations acted synergistically for each outcome. Individually, both multimorbidity<sup>17–19</sup> and functional limitations<sup>20,21</sup> have been shown to contribute to poor outcomes, including hospitalizations and death. Furthermore, frailty, which is a distinct clinical entity but overlaps with both multimorbidity and functional

**Table 2.** Association of functional limitations and multimorbidity with death, hospitalizations, and ED visits.

	Persons aged 60–69				Persons aged 70–79				Persons aged 80–89			
	N events	Rate <sup>a</sup>	HR (95% CI) <sup>b</sup>	p Value <sup>c</sup>	N events	Rate <sup>a</sup>	HR (95% CI) <sup>b</sup>	p Value <sup>c</sup>	N events	Rate <sup>a</sup>	HR (95% CI) <sup>b</sup>	p Value <sup>c</sup>
<b>Deaths</b>				<0.01				0.06				0.04
Neither	239	2.08	1.00 (ref)		268	3.07	1.00 (ref)		197	4.22	1.00 (ref)	
MM only	379	2.74	1.75 (1.49–2.06)		859	3.70	1.73 (1.50–1.98)		764	4.59	1.49 (1.28–1.75)	
FL only	53	3.30	2.91 (2.13–3.97)		80	4.09	2.74 (2.13–3.53)		120	4.83	1.91 (1.52–2.40)	
Both	219	3.87	5.34 (4.41–6.48)		544	4.50	4.16 (3.58–4.83)		837	5.16	2.86 (2.45–3.35)	
<b>Hospitalizations</b>				<0.01				<0.01				<0.01
Neither	246	4.81	1.00 (ref)		136	5.26	1.00 (ref)		66	5.67	1.00 (ref)	
MM only	379	5.42	1.78 (1.64–1.94)		485	5.81	1.65 (1.54–1.78)		291	6.17	1.64 (1.46–1.83)	
FL only	35	5.53	1.97 (1.64–2.35)		33	5.73	1.57 (1.27–1.94)		45	6.11	1.54 (1.30–1.83)	
Both	198	6.28	4.01 (3.53–4.56)		319	6.43	3.05 (2.66–3.49)		421	6.60	2.61 (2.31–2.93)	
<b>ED visits</b>				<0.01				<0.01				<0.01
Neither	726	5.42	1.00 (ref)		212	5.85	1.00 (ref)		88	6.35	1.00 (ref)	
MM only	1575	5.98	1.66 (1.54–1.80)		651	6.37	1.63 (1.50–1.76)		393	6.74	1.54 (1.38–1.71)	
FL only	146	6.04	1.58 (1.32–1.88)		45	6.24	1.44 (1.21–1.71)		51	6.62	1.34 (1.13–1.58)	
Both	1133	6.78	3.32 (2.93–3.77)		376	6.89	2.68 (2.42–2.96)		510	7.03	2.17 (1.93–2.45)	

MM: multimorbidity; FL: functional limitations; ED: emergency department; HR: hazard ratio; CI: confidence interval.

<sup>a</sup>Rates are presented per 1000 person-years.

<sup>b</sup>HRs were adjusted for age, sex, race, ethnicity, education, and marital status.

<sup>c</sup>p Values indicate the p value for the additive interaction.


limitations,<sup>22</sup> is associated with increased risks of hospitalizations, ED visits, and death.<sup>23–27</sup>

In the Medical Expenditure Panel Survey, persons with both functional limitations and multimorbidity experienced higher rates of ED visits and hospitalizations compared to persons with multimorbidity alone, and compared to the total adult population; however, outcomes among persons with functional limitations only were not reported.<sup>6</sup> In another study of persons with heart failure, those with both non-cardiovascular multimorbidity and functional limitations experienced the greatest risk of ED visits and hospitalization; however, those with functional limitations alone and those with both multimorbidity and functional limitations experienced similar mortality.<sup>28</sup> However, to our knowledge, our study is the first to specifically examine interactions of multimorbidity and functional limitations on adverse health outcomes and test whether having both imparts a larger risk of outcomes than expected. In the general population of older adults, we observed a synergistic effect of multimorbidity and functional limitations for all outcomes and found that patients who have both multimorbidity and functional limitations had the highest risk of ED visits, hospitalizations, and death. The interactions were more extreme for ED visits and hospitalizations and less extreme for death. Interestingly, we observed that persons with functional limitations alone had a higher risk of death than persons with multimorbidity alone, which suggests that the risk of death is driven more by functional limitations than multimorbidity. By contrast, similar risks of ED visits and hospitalizations were observed for persons with multimorbidity alone and with functional limitations

alone. Finally, for all outcomes, the magnitude of the interactions was strongest in the youngest age group and attenuated with increasing age. It has been postulated that aging results in a chronic dysregulation of multiple organ systems, and that multimorbidity is a landmark of loss of resilience and homeostasis.<sup>29</sup> Therefore, it can be hypothesized that having multimorbidity and functional limitations at younger ages is associated with accelerated aging, and results in poorer outcomes compared to persons who develop multimorbidity and functional limitations later in life. At advanced ages (e.g. 80–89 years), age itself is the major predictor of adverse health outcomes regardless of the number of chronic conditions or the number of functional limitations.

### Implications of our findings

Because nearly half of the persons in the top 5% of annual medical expenditures have at least one functional limitation along with multimorbidity,<sup>6</sup> and this top 5% accounts for 50% of the annual health-care spending in the United States,<sup>4,5</sup> it is imperative to identify interventions to improve the care and outcomes for these high-need patients. Although nearly 90% of high-need patients in the United States report that they have a treatment plan,<sup>30</sup> the needs of these patients may extend beyond clinical needs alone. Thus, to improve the outcomes of these high-need patients, a shift to more broadly address the patients' functional, social, and behavioral needs through social and community services in addition to traditional treatment plans may be required.<sup>2,8</sup> Furthermore, our results support



**Figure 3.** HRs (95% CIs) for death (top panel), hospitalization (middle panel), and ED visits (bottom panel) in four cohorts defined by functional limitation and multimorbidity status. The HRs for death were estimated from a Cox proportional hazards regression model, whereas the HRs for hospitalizations and ED visits were estimated using Andersen–Gill models. HRs were adjusted for age, sex, race, ethnicity, education, and marital status. The cohort of persons with neither multimorbidity nor functional limitations served as the referent cohort. CI: confidence interval.

the need for interventions to prevent the onset of multimorbidity and functional limitations at all ages, but particularly at younger ages.

### Limitations and strengths

Our study has limitations that deserve mention. First, we relied on electronic ascertainment of chronic conditions, and because we did not validate the diagnoses, some patients may have been misclassified. However, we required two occurrences of a code (either the same diagnostic code or two different diagnostic codes within the same code set) separated by more than 30 days to minimize misclassification. We expect that any misclassification would not differ systematically between cohorts, and thus would not substantially affect our estimates. Second, we excluded patients who did not have available information on ADLs, which was nearly 20% of the population. The patients with missing ADL information tended to be younger and had fewer chronic conditions than those included in the analyses, and their exclusion could have biased our results. However, we expect that our results are most likely biased toward the null, and thus the estimates presented in our paper may be conservative. Third, the proportion of persons in our cohort with multimorbidity and functional limitations would have differed if we had used different cutoff points. For example, we used a list of 18 chronic conditions to define multimorbidity, and fewer patients would have been considered to have multimorbidity if a smaller number of chronic conditions had been used. Fourth, we did not consider severity of conditions or treatment for conditions when defining multimorbidity. Fifth, persons may have accumulated chronic conditions and functional limitations during follow-up, but we did not account for these intervening events in our results. Finally, our population was primarily White, and thus our results may not be generalizable to other populations with different racial or ethnic characteristics. However, comparison of the REP population to Census data revealed that this population is representative of the population of the Upper Midwest and of a large segment of the entire US population.<sup>10</sup>

Our study also has several strengths, including the large sample size and the comprehensive capture of all health-care visits and outcomes in the population through the resources of the REP.<sup>9–12</sup> In addition, the large data set allowed us to stratify patients into four cohorts and to study both individual and joint effects of multimorbidity and functional limitations on several adverse health outcomes. This design allowed us to show that functional limitations are more strongly associated with poor outcomes than multimorbidity.

### Conclusion

In older adults, the risk of ED visits, hospitalizations, and death was highest among persons with both multimorbidity



and functional limitations, underscoring the importance of incorporating both multimorbidity and functional limitations when stratifying patients to predict risk. Furthermore, although multimorbidity and functional limitations act synergistically on these outcomes, the magnitude of the interactions attenuated with increasing age. Therefore, interventions to prevent the onset of multimorbidity and functional limitations are warranted at all ages, but will be most impactful at younger ages.


### Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, the National Institute on Aging (R01 AG052425), and was made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01 AG034676.

### ORCID iD

Alanna M Chamberlain  <https://orcid.org/0000-0003-1888-9584>

### Supplemental material

Supplemental material for this article is available online.

### References

- Ortman JM, Velkoff VA and Hogan H. *An aging nation: the older population in the United States*. Current Population Reports. Washington, DC: US Census Bureau, 2014, pp. 25–1140.
- Blumenthal D, Chernof B, Fulmer T, et al. Caring for high-need, high-cost patients—an urgent priority. *N Engl J Med* 2016; 375: 909–911.
- Centers for Disease Control and Prevention. *The state of aging and health in America 2013*. Atlanta: Centers for Disease Control and Prevention, US Department of Health and Human Services, 2013.
- Cohen SB. *Differentials in the concentration of health expenditures across population subgroups in the U.S., 2013*. Rockville: Statistical Brief (Medical Expenditure Panel Survey (US)), 2015.
- Mitchell EM. *Concentration of health expenditures in the U.S. civilian noninstitutionalized population, 2014*. Rockville: Statistical Brief (Medical Expenditure Panel Survey (US)), 2016.
- Hayes SL, Salzberg CA, McCarthy D, et al. *High-need, high-cost patients: who are they and how do they use health care? A population-based comparison of demographics, health care use, and expenditures*. Issue Brief (Commonw Fund). 2016; 26: 1–14.
- Huffstetler E and Quincy L. *Addressing the unmet medical and social needs of complex patients*. Report no. Research brief no. 17, 2017. Altarum Healthcare Value Hub. 2017. [https://healthcarevaluehub.org/application/files/2715/6375/9488/Hub-Altarum\\_RB\\_17\\_-\\_Addressing\\_Needs\\_of\\_Complex\\_Patients.pdf](https://healthcarevaluehub.org/application/files/2715/6375/9488/Hub-Altarum_RB_17_-_Addressing_Needs_of_Complex_Patients.pdf) (accessed 22 January 2019).
- Long P, Abrams M, Milstein A, et al. *Effective care for high-need patients: opportunities for improving outcomes, value, and health*. Washington, DC: National Academy of Medicine, 2017.
- Rocca WA, Yawn BP, St Sauver JL, et al. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. *Mayo Clin Proc* 2012; 87: 1202–1213.
- St Sauver JL, Grossardt BR, Leibson CL, et al. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. *Mayo Clin Proc* 2012; 87: 151–160.
- St Sauver JL, Grossardt BR, Yawn BP, et al. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. *Am J Epidemiol* 2011; 173: 1059–1068.
- St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. *Int J Epidemiol* 2012; 41: 1614–1624.
- Goodman RA, Posner SF, Huang ES, et al. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. *Prev Chronic Dis* 2013; 10: E66.
- US Department of Health and Human Services. *Multiple chronic conditions—a strategic framework: optimum health and quality of life for individuals with multiple chronic conditions*. Washington, DC: US Department of Health and Human Services, 2010.
- Nelson WB. *Recurrent events data analysis for product repairs, disease recurrence, and other applications (ASA-SIAM series on statistics and applied probability)*. Philadelphia: Society for Industrial and Applied Mathematics, 2003.
- Li R and Chambless L. Test for additive interaction in proportional hazards models. *Ann Epidemiol* 2007; 17: 227–236.
- Gruneir A, Bronskill SE, Maxwell CJ, et al. The association between multimorbidity and hospitalization is modified by individual demographics and physician continuity of care: a retrospective cohort study. *BMC Health Serv Res* 2016; 16: 154.
- Nunes BP, Flores TR, Mielke GI, et al. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. *Arch Gerontol Geriatr* 2016; 67: 130–138.
- Wang HHX, Wang JJ, Lawson KD, et al. Relationships of multimorbidity and income with hospital admissions in 3 health care systems. *Ann Fam Med* 2015; 13: 164–167.
- Luppa M, Luck T, Weyerer S, et al. Prediction of institutionalization in the elderly. A systematic review. *Age Ageing* 2010; 39: 31–38.
- Millán-Calenti JC, Tubío J, Pita-Fernández S, et al. Prevalence of functional disability in activities of daily living (ADL), instrumental activities of daily living (IADL) and



- associated factors, as predictors of morbidity and mortality. *Arch Gerontol Geriatr* 2010; 50: 306–310.
22. Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. *J Gerontol A Biol Sci Med Sci* 2004; 59: 255–263.
  23. Chamberlain AM, Finney Rutten LJ, Manemann SM, et al. Frailty trajectories in an elderly population-based cohort. *J Am Geriatr Soc* 2016; 64: 285–292.
  24. Chang SF, Lin HC and Cheng CL. The relationship of frailty and hospitalization among older people: evidence from a meta-analysis. *J Nurs Scholarsh* 2018; 50: 383–391.
  25. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *Lancet* 2013; 381: 752–762.
  26. Rockwood K, Song X and Mitnitski A. Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. *Can Med Assoc J* 2011; 183: E487–E494.
  27. Shamliyan T, Talley KM, Ramakrishnan R, et al. Association of frailty with survival: a systematic literature review. *Ageing Res Rev* 2013; 12: 719–736.
  28. Manemann SM, Chamberlain AM, Roger VL, et al. Multimorbidity and functional limitation in individuals with heart failure: a prospective community study. *J Am Geriatr Soc* 2018; 66: 1101–1107.
  29. Fabbri E, Zoli M, Gonzalez-Freire M, et al. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. *J Am Med Dir Assoc* 2015; 16: 640–647.
  30. Sarnak DO and Ryan J. *How high-need patients experience the health care system in nine countries*. Issue Brief (Commonw Fund). 2016; 1: 1–14.